drugset / Trial / NCT06888752
LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma
Not yet recruiting
35 enrolled
First Affiliated Hospital of Wenzhou Medical University
Beijing Boren Hospital · collabFirst People's Hospital of Hangzhou · collab
NaSingle-groupOpen-labelTreatment
Summary
A prospective, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61SQ in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2025-03-20
- Primary completion
- 2030-06-30
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-M61SQ | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |